According to a study presented at the American Academy of Ophthalmology’s annual meeting in Chicago, investigational ...

An investigational antibody demonstrated an ability to preserve vision in people with geographic atrophy from dry age-related ...

PYC Therapeutics (ASX:PYC) has announced significant progress in its efforts to develop RNA-based precision medicines for ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder ...

You can still live a full life with geographic atrophy (GA). Even though your vision may be different, GA doesn’t lead to total blindness. You can use your remaining vision and make certain ...

Apellis Pharmaceuticals (NASDAQ:APLS) shares fell sharply on Tuesday after the Waltham, Massachusetts-based biotech reported lower-than-expected Q3 2024 financials as U.S. net sales from its eye ...

Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...

In an interview with Ophthalmology Times, Quan Dong Nugyen, MD, MSc, discusses ongoing research into Tinlarebant, an ...

Apellis stock plunged Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations.

CHICAGO -- An investigational dual-action inhibitor for geographic atrophy (GA) significantly slowed disease progression and ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has dosed its first patient in a clinical trial for its innovative ...